|
|
Post by loparn on Oct 23, 2016 16:22:49 GMT
The Swedish biotech company WntResearch has a very promising drug candidate Foxy-5 targeting the lethal process of metastasis which accounts for around 90 % of the deaths in cancer. The focus is on breast, colon and prostate cancer. According to my valuation the WNT stock has a fundamental risk adjusted value of some 15-25 times the current value at the Swedish list "Aktietorget". I have made a very short English version of my extremely long Swedish analysis here : www.infoom.se/mysite/index.php?sida=80579&user=9801You can also read about WNT on their home page www.wntresearch.com |
|
|
|
Post by loparn on Nov 13, 2016 20:14:53 GMT
Sooner or later the market will understand why Foxy-5 could be the first antimetastasis drug ever. These Kaplan-Meier-curves comparing Foxy-5:s "target" molecule Wnt-5a in breast cancer patients show the potential cancerres.aacrjournals.org/content/canres/62/2/409/F6.large.jpg?width=800&height=600&carousel=1 ...if Foxy-5 could do the same in patients with low or no Wnt-5a expression in their primary tumors. The curves show a difference of over 8 years in progressionfree median survival depending on the natural Wnt-5a expression. |
|
|
|
Post by loparn on Nov 18, 2016 18:27:11 GMT
|
|
|
|
Post by loparn on Nov 24, 2016 8:06:56 GMT
|
|
|
|
Post by loparn on Nov 24, 2016 19:25:53 GMT
Today's very promising newsrelease from WntResearch proves that Foxy-5 reaches its receptor Frizzled-5, which also Wnt-5a can bind to, and importantly Wnt-5a is associated with around 2-8 years prolonged life in breast, colon and prostate cancer due to its antimetastatic effect. Many in vitro studies prove that Foxy-5 and Wnt-5a have the same effect against metastasis on different types of human breast, colon and prostate cancer cells, and with today's news Foxy-5 should do very much the same as far as survival effect is concerned, and prove it in pivotal Phase II-studies and become a success with a rather high probability. A deal with Big Pharma is now very likely to occur within months. WntResearch stock should reach a new ATH. www.aktietorget.se/NewsItem.aspx?ID=81128Short English analysis : www.infoom.se/mysite/index.php?sida=80579&user=9801 |
|
|
|
Post by loparn on Nov 29, 2016 11:40:52 GMT
|
|
|
|
Post by loparn on Dec 6, 2016 6:28:03 GMT
The stock reached SEK 49 a few days after the Nov 24 newsrelease (when it started at 27.40 from the day before) but a deep rebound to 34 when a lot of (scared?) traders have taken profits (or loss). WNT.ST should reach a higher new bottom soon (compared to ~SEK 20 this summer-autumn) in my opinion because the news were really really important. The Phase Ib study proves that Foxy-5 can signal through Frizzled-5 in patients making it possible to mimick the antimetastatic effects of Wnt-5a (which in turn have been showed to be similar between Foxy-5 and Wnt-5a in many in vitro and in vivo experiments, mostly with human cancer cells when either of these signal through Frizzled-5) - the protein that is associated with around 2-8 years prolonged median survival in breast, colon and prostate cancer patients with low or no Wnt-5a in their primary tumor. www.aktietorget.se/NewsItem.aspx?ID=81128 |
|
|
|
Post by loparn on Dec 9, 2016 15:49:17 GMT
News today : "WntResearch AB has accepted an invitation to present the company at the 9th Annual Biotech Showcase Conference in San Francisco, USA. The presentation will take place on 11 January 2017. During the conference, WntResearch will also hold individual meetings with representatives of global pharmaceutical companies that have showed interest in the company’s drug candidates. Biotech Showcase is an annual international conference that brings together investors and senior executives from the international biotech and pharmaceutical industries." For me it is obvious that WntResearch could reach a fine partner deal within weeks or months regarding the presumably first anti-metastasis drug ever in breast, colon and prostate cancer, and that will be a huge WNT.ST stock trigger. www.aktietorget.se/NewsItem.aspx?ID=81381 |
|
|
|
Post by loparn on Dec 13, 2016 19:50:29 GMT
|
|
|
|
Post by loparn on Jan 5, 2017 13:25:12 GMT
A move up today by 11 % before the presentation i San Francisco January 11. finance.yahoo.com/quote/WNT.ST/?p=WNT.ST" Wed, January 11 at 9:00 AM WntResearch is developing a unique cancer treatment aiming at counteracting tumor spreading, i.e. metastases. The results from a completed phase 1-study show good safety, pharmacokinetics and indications of relevant biological activity. The company is now seeking partnerships to develop Foxy-5 in phase II/III for one or more cancer indications." www.ebdgroup.com/bts/core/presenting-companies.php?_ga=1.163155644.1025023803.1481287190Obviously they see a possibility to get different partners to the different Foxy-5 cancer types. Foxy-5 has a potential in more cancers than breast, colon and prostate, for example liver cancer, thyroid cancer etc. |
|
|
|
Post by loparn on Jan 9, 2017 7:36:35 GMT
|
|
|
|
Post by loparn on Jan 12, 2017 16:46:41 GMT
The CEO made a very good presentation in my opion, but the market didn't like one slide that mentioned a partner deal AFTER the Phase II study start but one could probably not rule out a deal before that.
|
|
|
|
Post by loparn on Feb 5, 2017 18:17:50 GMT
WntResearch and the University of Copenhagen to investigate potential interaction between Foxy-5 and cancer immunotherapy : "WntResearch’s leading drug candidate Foxy-5 has in an ongoing clinical study shown a biological effect in cancer patients. The company will now commence a collaboration with Associate Professor Peter Holst at the Department of Immunology and Microbiology at the University of Copenhagen, in order to investigate if and how Foxy-5 can be combined with immunotherapies in treating cancer. ”If Foxy-5 – besides its anti-metastatic qualities – can be combined and function well together with new immunotherapies, further interesting possibilities open up for the drug candidate to become a key component in treating cancer in the future” says Henrik Lawaetz, CEO, WntResearch AB. The aim of the collaboration, which is based on pre-clinical experimental models, is to increase the knowledge base about important immunological factors connected to metastasis and how Foxy-5 can affect these factors." www.aktietorget.se/NewsItem.aspx?ID=81957 |
|
|
|
Post by loparn on Feb 23, 2017 13:37:49 GMT
|
|
|
|
Post by loparn on Mar 4, 2017 11:45:37 GMT
|
|
|
|
Post by loparn on Mar 18, 2017 20:02:34 GMT
Short summary of - Why should the Foxy-5 project become successful from a scientific point of view ? 1. The target natural protein Wnt-5a is correlated with an increased median survival in breast, colon and prostate cancer of around 2-8 years. 2. Wnt-5a and Foxy-5 both separately show the same antimetastatic mechanisms on a cell and molecular level in vitro on different human breast, colon and prostate cancer cell types when Wnt-5a and Foxy-5 bind to their common receptor Frizzled-5 , thus explaining why 1. occurs and importantly that Foxy-5 can do very much the same as Wnt-5a. (This is also the case in vitro for mouse cancer cells and mouse cancer in VIVO but this is not that important anymore due to 3. below, but nevertheless a confirmation since Wnt-5a and Frizzled receptors are highly conserved between species.) 3. Foxy-5 has recently been shown in the clinical Phase Ib study to be able to reach the cancer cells in patients who have low or none Wnt-5a in their tumor cells and signal in a relevant way on mRNA level, thus proving it can initiate Wnt-5a-signaling through their common receptor Frizzled-5. www.aktietorget.se/NewsItem.aspx?ID=811281.- 3. taken together => there should be a high probability for success with Foxy-5 in a well designed Fas II-study. The (dumb) stock market do not agree since the market capital is just some USD 50 million. It waits for either issuing of new stocks or partner deal(s) with Big Pharma(s) or a take over bid. |
|
|
|
Post by loparn on Mar 21, 2017 8:47:33 GMT
Newsrelease : "21 MAR 2017 - 08:20 WntResearch: WntResearch announces positive results from clinical study with drug candidate Foxy-5 WntResearch today announces that the company has obtained positive results from the analyses of patient tumour tissue samples before and after treatment in a Phase 1b study with Foxy-5 – a drug candidate intended to inhibit tumours from spreading in cancer patients. Based on the obtained results, the company has defined the dose level for the upcoming Phase 2 study, which was one of the objectives with this clinical study. In the Phase 1b study, a total number of 12 patients with advanced cancer in colon, prostate or breast have been treated with Foxy-5. Gene expression analyses show that the second highest of four investigated dose levels results in the best biological effect in patient tumour tissue. The safety profile is continuously favourable and all the tested dose levels were well tolerated. ” The positive results have made it possible to choose a dose level with clear biological effect in the treated patients’ tumour tissue for evaluation in the upcoming Phase 2 study. The biological effect that has been observed strengthens us in our belief that our drug candidate has a strong potential to reach and affect tumours in humans”, says Henrik Lawaetz, CEO, WntResearch AB. Further data for the chosen dose level will be generated in the now initiated concluding part of the study, a so called ”expansion group” with three patients. The Phase 2 study is planned to commence later this year." www.wntresearch.com/investor-media/news-releases.aspx?Id=82730&category=eNewsItem |
|
|
|
Post by loparn on Mar 22, 2017 19:42:17 GMT
The CSO Tommy Andersson has been quoted to have said today after a ( very good) presentation in Stockholm that 3 Big Pharma is interested in Foxy-5. The presentation was held in Swedish though.
|
|
|
|
Post by loparn on Apr 18, 2017 8:17:26 GMT
This is why the WntResearch antimetastatic Wnt-5a -mimicking drug candidate Foxy-5 should become a success :
Natural protein Wnt-5a in patients with breast, colon and prostate cancers --> Frizzled-5 receptor =>
several proved antimetastatic mechanisms on human cancer cells in breast, colon and prostate cancers =>
a very big already proved beneficial survival effect of a high Wnt-5a expression compared to a low or no expression in over 2000 patients with breast, colon and prostate cancers thus has been explained mechanistically.
=>
Start treatment soon after diagnosis of patients with breast, colon and prostate cancers and low or no expression of Wnt-5a with the Wnt-5a -mimicking drug candidate Foxy-5 --> Frizzled-5 receptor =>
several proved antimetastatic mechanisms on human cancer cells in breast, colon and prostate cancers =>
a qualitative and probably quantitative similar beneficial survival effect of Foxy-5 thus is expected in patients with breast, colon and prostate cancers with low or no expression of Wnt-5a , since Foxy-5 binds to the same receptor Frizzled-5 as Wnt-5a and both have been shown to generate similar or same antimetastatic effects, and importantly Foxy-5 was shown in the Phase 1b study to reach its receptor in patients with breast, colon and prostate cancers and low or no expression of Wnt-5a.
|
|
|
|
Post by loparn on Apr 21, 2017 8:26:53 GMT
|
|
